Index

Note: Page references in italics refer to Figures; those in bold refer to Tables; those page references with b denotes Box.

ABI see ankle brachial index (ABI)
abnormal glucose metabolism (AGM), 38
Accountable Care Organizations (ACOs), 530
ACE inhibitors see angiotensin-converting enzyme (ACE) inhibitors
acid–base balance, 230–1
Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, 47, 354
activities of daily living (ADL) assessment, 49
acute pain, 458
adipocyte hyperplasia, 188
adipocytokines, 188
adiponectin, 5
adult respiratory distress syndrome, 236
advanced glycosylation end-products (AGEs), 59, 420
age-adjusted relative risk for type 2 diabetes, 20
age groups, definition, 30
age-related macular degeneration, 109–10
alcohol, 4, 253
α-blockers, 98
α-glucosidase inhibitors, 21, 96–7
cardiovascular risk factors, 307
efficacy, 307
mechanism of action, 306–7
safety and tolerability, 307
Alzheimer's disease (AD), 427–8
Android-specific diabetes apps, 169
anemia, 253
angiotensin-converting enzyme (ACE) inhibitors, 5, 75–6, 344
angiotensin receptor blockers (ARBs), 76, 344
ankle brachial index (ABI), 58, 63, 63
anorexia of aging, 241
anorexia–sarcopenia–sachexia triad, 242
antihypertensive medication, 75–6
anti-lipid lowering therapy treatment, 58
anti-platelet therapy, 199
arterial tree stiffening, 68
artificial nutrition, 257–8
aspirin therapy
   cardiovascular risk, 78
   metabolic syndrome, 199
   primary and community care, 383
asymptomatic bacteriuria (ASB), 421
atenolol, 76
atherosclerosis, 57–9, 60, 67, 68, 69
atorvastatin, 199
Auditory Verbal Learning Test (AVLT), 427
autonomic nervous system, 90
autonomic neuropathy
   autonomic dysfunction, 128–9
   cardiovascular autonomic neuropathy, 129–30
cardiovascular disease, 129
   erectile dysfunction, 129
gastroparesis, 129
genitourinary system, 129
sudomotor dysfunction, 129
barriers, insulin therapy, 325–6, 326b
basal-bolus insulin regimens, 329
basal insulin regimens, 328
basal insulin secretion, 327
Beck Depression Inventory-Fast Screen (BDI-FS), 439
Benton Visual Retention Test (BVRT), 427
β-blockers, 76, 159, 197, 344, 383, 529
bezafibrate, 199
bicarbonate therapy, 235
biguanides
   buformin (1-butylbiguanide), 300
cardiovascular risk factors, 301–2
cautions and contraindications, 302–3
clinical outcomes, 301–2
efficacy, 301
mechanism of action, 300–1
metformin (dimethylbiguanide), 300
phenformin (phenethylbiguanide), 300
tolerability, 303
blood glucose tests, 32–4
body mass index (BMI), 20
bromocriptine, 314
brown adipose tissue (BAT), 188
buformin (1-butylbiguanide), 300
calcium, 254
calcium channel blockers (CCBs), 76, 98, 344
CAM see complementary and alternative therapies/medicine (CAM)
cancer, 419–20, 459
candidiasis, 49
capillary blood ketone testing, 399
 captopril, 76, 383
carbohydrate metabolism, 3–4
carbohydrates and fats intake, 250–1
cardiocascular autonomic neuropathy, 129–30
cardiocvascular diseases (CVD), 38
prevalence, 69
risk factor, 21
cardiocvascular risk
aspirin therapy, 72b, 78
dyslipidemia, 72b, 73–5
hypercoagulability, 78
hyperglycemia, 72b, 77–8
hypertension, 72b, 75–6
lifestyle modification, 71, 72b, 73
metabolic syndrome, 72b, 73
multifactorial intervention, 78
in older people with diabetes, 71b
primary and community care, 382
reverse metabolism, 79
risk reduction, 64
cardiocvascular system
aging effect, 68, 69b
diabetes effect, 69, 69b
Caregiver Strain Index, 484
care homes, diabetes in, 360–73
assessing efficacy and efficiency of, 371, 372
complications and co-morbidity, 363–4
epidemiology, 361–3, 362
eye care, 370–1
foot care, 370
improving care, 368
management problems, 364–5
multidisciplinary diabetes care, 369
nursing care, 369–70
organization of diabetes care in, 365–8
developing standards, 366–8
setting standards, 365–6
patient healthcare settings, 372
prevalence, 363
responsibility of physician, 369
setting standards, 365–6
sustaining, 371–2
in UK, 361
carers
benefits of, 512–13, 513
care managers, 507
care providers, 507–8
delivery responsibility, 507
effect of caring, 509–10
family burden, 506
health professionals and policy makers, 505
men vs. women, 506
needs, 510–12
Oldest Old Study, 509
role, 506–7
structured education, 506
subjective burden, 506
carpal tunnel syndrome, 126, 127
carvedilol, 197
cataract, 109
cerebral edema, 235
cGA see comprehensive geriatric assessment (CGA)
Charcot’s neuropathy, 114–15
Charlson Index, 216, 217
CHD see coronary heart disease (CHD)
chlorothalidone, 345
cholecalciferol, 254
chromium, 4, 255
chronic diarrhea, 261
chronic inflammation, 89–90
chronic inflammatory demyelinating polynueopathy (CIDP), 128
chronic kidney disease (CKD), 84–99
DKD
albuminuria, 92–3
glomerular filtration rate, 93–4
pathophysiological mechanisms, 87, 87, 93
epidemiology, 85–7
hyperglycemia
α-glucosidases inhibitors, 96–7
DPP-4 inhibitors, 97
general considerations, 96
glucagon-like-peptide-1 mimetics, 97
insulin, 97
meglitinides, 96
metformin, 96
in pre-diabetes, 96
sodium-glucose cotransporter 2 inhibitors, 97
sulfonylureas, 96
hypertension
α-blockers, 98
calcium-channel blockers, 98
diuretics, 98
dyslipidemia, 98
fibrates, 98
general considerations, 97
RAAS action, 97–8
statins, 98
thiazide, 98
metabolic alterations
  advanced glycation end products, 88
  aging, 92
dyslipoproteinemia, 89
genetic load and fetal programming, 91
high blood pressure, 91–2
hormonal influences, 90
inflammation, 89–90
lifestyle and habits, 91
obesity, 91
oxidative stress, 88–9
polyol and hexamine contents, 87–8
protein kinase C, 88
renal hemodynamics, 89
uric acid, 89
treatment
  dietary plan, 95–6, 96
  physical activity schedule, 95
  sedentary lifestyle and overweight, 95
chronic pain, 458–9
clofazimine, 64
CKD see chronic kidney disease (CKD)
claudication, 61
clinical trials
  clinical interventions, 533
  elderly subjects
    EU population, 535
    informed consent, 539–40
    MID-Frail study, 540–1
    outcome, 540
    RCT, 535
    recruitment, 537, 538–9, 539
    research design, 537
    retention, 540
  EMA, 533–4
  GCP, 533
  nutritional interventions/drug trials, 535, 536
  search strategy, 534, 535
  types of, 534
clock-drawing test (CDT), 50, 429–31
clopidogrel, 64
cognitive behavioral therapy (CBT), 442
cognitive dysfunction, 15–16, 353
  AD, 427–8
  blood pressure control, 428
cognitive impairment, 426, 427
deletious effects, 428
detection
  early recognition, 429, 429
  methods, 430–1
development, 426
examination, 427
exclusion of depression, 432–3
further investigations, 433, 433
  and glycemic control, 429
  and insulin resistance, 431–2
  and self-care, 431–2
  Rancho Bernardo Study, 427
  recent developments, 433–4
type 1 and 2 diabetes, 428
cognitive impairment, 273, 383–4
treatment
  clofazimine, 313–14
collaborative care, 443
  chronic resistance and endurance training, 269, 271
communication difficulties, 364–5
community care see primary and community care
comorbidity, diabetes
cancer, 419–20
fractures, 420–1, 421, 422
hearing impairment, 423
lower urinary tract symptoms
  epidemiology, 422
  potential explanatory factors, 423
treatment, 423
non-alcoholic fatty liver disease
  definition, 416
  dipeptidyl peptidase 4 inhibitors, 419
  epidemiology, 417
  genetic basis, 417
  GLP-1, 419
  metformin, 417, 418
  pathogenesis, 417
  thiazolidinediones, 417, 419
  visceral fat, 417
obstructive sleep apnea
  definition, 415
  epidemiology, 415, 415–16
  hypothalamic-pituitary-adrenal axis, 416
  intermittent hypoxia, 416
  sympathetic nervous system activity, 416
treatment, 416
periodontal disease
  definition, 423
  epidemiology, 424
  pathophysiology, 424
treatment, 424
complementary and alternative therapies/medicine (CAM), 465, 466, 481–2
comprehensive geriatric assessment (CGA), 44–50, 219–20
  advantages, 44–5
  benefits of, 219
  definition, 44
  functional domain, 46, 47, 49
  medical domain, 45, 47–9
  psychological/mental domain, 46, 47, 49–50
  social domain, 47, 48, 50
comprehensive geriatric evaluation (CGE), 30–1
computed tomographic angiography, 64
confusion assessment method (CAM), 50
congestive heart failure, 21, 92, 313, 344, 419, 460
constipation, 252
continuous glucose monitoring (CGM) trial, 530
copper, 255
coronary artery disease, 185
coronary heart disease (CHD), 67–79 see also cardiovascular diseases (CVD);
epidemiology of, 69–70
morbidity, 67
prevention and management, 71–9, 72b
 coronary risk equivalent, diabetes as, 67
corticosteroids, 477, 481–3
cortisol, 8
cost-effectiveness
blood pressure control, 529
care management and coordination, 530–1
cholesterol level, 529
diabetes prevention, 527–8
glucose control, 528–9
prevalence of, 526
principles of, 526–7, 527
cost-effectiveness analysis (CEA), 526–7, 527
cranial mononeuropathies, 127
C-reactive protein (CRP), 5, 58
critical limb ischemia, 62
CVD see cardiovascular diseases (CVD)
cystatin C, 94
cytomegalovirus, in human immunodeficiency, 109
Da Qing study, 23–4, 26
dementia, 383–4
 hypertension, 346
 insulin therapy, 332, 332
 primary and community care, 383–4
 risk of, 355
 sensory disability, 142
depression, 384
cognitive dysfunction, 440
and diabetes interaction, 438–9, 439
and diabetes relationship, 438
diagnosis, 439, 440b
ethnicity, 440
management, 440b–2b, 441–3
mortality, 441
physical function, 440–1
depression care management, 441
diabetes care, inpatient, 395–7, 396
admissions, 397
discharge coordinators, 406
hyperglycemia
 diabetes education, 401
diabetic foot, 401–2
diabetic ketoacidosis, 398–9
discharge planning, 403
discharge types, 405, 405
evidence-based criteria, 404
hyperosmolar hyperglycaemic state, 399–400
hypoglycemia, 400–1
initial discharge assessment, 403
meal timings and eating patterns, 403, 403
perioperative care, 402
safe and timely discharge, 403, 403
ThinkGlucose assessment tool, 403–4, 404
medication, 398, 398
roles and responsibilities, 405, 406
whole-system approach, 397–8
diabetes distress, 496
diabetes education, 401
assessment
clinical and functional factors, 493–4, 493
clinical and functional factors, 493–4, 495
cognitive function, 496–7
co-morbidity and complications, 494
health literacy, 497–8, 498
important areas, 493, 493
polypharmacy, 494–5
psychological factors, 495–6
social factors, 496
and behavioral support interventions
cognitive restructuring technique, 500
goal setting, 499–500, 500
group vs. individual, 499, 499
lifestyle intervention vs. standard group, 500
complications dominate, 493
diagnosis, 492
health maintenance/prevention phase, 492
onset of early complications, 492–3
self-care, 491
Diabetes Prevention Program (DPP), 21, 23, 526
Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study (DPP/DPPOS), 24–7
Diabetes Problem-Solving Interview
(Toobert and Glasgow), 431
diabetes-related iPhone apps, 169
diabetes specialist nurses, 369–70
diabetic amyotrophy, 127
diabetic cardiomyopathy, 69
diabetic foot, 61, 262, 370
amputation, 121
assessment
history and physical examination, 116
screening, neuropathy, 116–17, 117
screening, peripheral vascular disease, 117–18
in care homes, 370
Charcot’s neuropathy, 114–15
classification (Wagner), 116
corrective surgery, 121
diabetic neuropathy, 114
elderly patients, 114
hyperglycemia, 401–2
infection control, 118–19
PAD, 115
poor healing, 115
primary and community care, 382
principles of management, 118
treatment, 118
wound condition
dehbridement, 119
dressings, 120
HBOT, 121
NPWT, 121
pressure modulation, 120
revascularization, 120–1
diabetic ketoacidosis (DKA), 233
clinical and laboratory follow-up, 235
clinical presentation, 231
features, 229
hyperglycemia, 398–9
laboratory findings, 232
pathogenesis, 229–31
treatment, 232
diabetic kidney disease (DKD)
pathophysiological mechanisms, 87, 87, 93
screening and diagnosis
albuminuria, 92–3
glomerular filtration rate, 93–4, 94
diabetic lumbosacral radiculoplexus neuropathy (DLPRN), 127
diabetic nephropathy see diabetic kidney disease (DKD)
diabetic neuropathy, 144
CIDP, 128
diabetic autonomic neuropathy, 128–30
diagnosis and evaluation, 130–2, 131
DSPN, 126
local mononeuropathies, 126–7
frequency, development, 125–6
management, 132–4
radiculoplexus neuropathy, 127–8
treatment, 130
diabetic peripheral neuropathy (DPN)
CIDP, 128
diabetic autonomic neuropathy, 128–30
DSPN, 126
local mononeuropathies, 126–7
radiculoplexus neuropathy, 127–8
diabetic retinopathy, 110
diabetic sensorimotor polyneuropathy (DSPN), 126
dietary approach to stop hypertension (DASH) diet plan, 342, 343
dietary modifications, 342–3
Digit Symbol Substitution (DSS), 427–8
digoxin, 450
dipeptidyl peptidase-4 (DPP-4) inhibitors, 7, 97, 419
allogliptin, 309
efficacy, 309
GIP, 307
GLP-1, 307–8
incretin effect, 307
linagliptin, 309
place, 309
profiles, 307, 308
safety and tolerability, 309–10
sitagliptin, 308
vildagliptin, 308–9
disability, 218–19, 220
functional, 16, 17, 36, 333
sensory disability, 142 (see sensory disability)
type 2 diabetes, 171
discharge
coordinators, 406
initial assessment, 403
planning, 403
safe and time, 403, 403
types, 405, 405
district (community) nurses, 370
diuretics, 76, 98, 344
DKA see diabetic ketoacidosis (DKA)
DKD see diabetic kidney disease (DKD)
doxazosin, 197
DPN see diabetic peripheral neuropathy (DPN)
DPP see Diabetes Prevention Program (DPP)
DPP-4 inhibitors see dipeptidyl peptidase-4 (DPP-4) inhibitors
Dupuytren’s contracture, 461
dyslipidemia, 98, 383
  cardiovascular risk, 73–5
  insulin resistance, 190–1
  risk factors of PAD, 58
dyslipoproteinemia, 89
dysphagia, 262

Early Treatment Diabetic Retinopathy Study (ETDRS), 110
education and multidisciplinary car, 334
eHealth, 168 see also mHealth, type 2 diabetes
electrolytes, 230–1
endothelial dysfunction, 68
endothelins (ET), 90
endovascular revascularization, 65
endurance training, 268, 269, 273
enteral tube feeding (ETF), 258–62
environmental factors, 4
epinephrine, 8
erectile dysfunction, 129
estimated glomerular filtration rate (eGFR) measurements, 94
ethnicity, 38, 440
European Medical Agency (EMA), 533–4
European Society of Hypertension (ESH), 339
evidence-based review, 108, 108b
exenatide, 97
exercise, 38, 64–5, 71, 251–2, 273
eye care, 370–1
Facial Recognition Test (FRT), 427
falls, 287–8, 459
    assessment, outpatient diabetes clinics, 451, 451–4, 452, 453
definition, 448
    incidence of, 448
    post-fall syndrome, 449
risk factors
    cohort study, 449
    fracture, 449
    hypoglycemia with insulin treatment, 450
    OH, 450
    Women's Health and Aging Study, 449
fasting plasma glucose (FPG), 33, 36
fecal incontinence, 364
fiber intake, 252
fibrates, 98, 199
Finger Tapping Test, 427
Finnish Diabetes Prevention Study, 24, 26
fluids, 230–1
fluid therapy, 232, 234
folate-rich foods, 255
Fontaine's stages, 61, 62
foot care, 134, 370
foot ulceration, 370, 401 see also diabetic foot fractures, 420–1, 421
frailty, 215–18, 220
type 2 diabetes, 171
Framingham risk score, 185
functional impairment, 39
gabapentin, 133, 462
gastroparesis, 129, 260
gemfibrozil, 199
general considerations, 96, 97
genetic factors, 3
genetic load and fetal programming, 91
Geriatric Depression Scale-15 (GDS-15), 439
geriatric syndromes, 44
gingivitis, 262
gingko biloba, 64
glargin insulin, 21
glaucoma, 109
glibenclamide (glyburide), 96
gliclazide, 96
glimepiride, 96
glinides, 227
glipizide, 96
global impact, 107, 107b
glucagon, 8, 9
glucagon-like peptide-1 (GLP-1) inhibitors, 307–8, 419
glucokinase activators, 314
glucose counter-regulation, 8–9
    glucose-dependent insulinotropic peptide (GIP), 307
    glucose disposal rates, insulin-mediated, 5, 6
glucose effectiveness, 7, 7–8
    glucose-induced insulin release, 5, 6
    glucose level, 34
    glucose lowering drugs
        α-glucosidase inhibitors
            cardiovascular risk factors, 307
            efficacy, 307
            mechanism of action, 306–7
            safety and tolerability, 307
        biguanides
            buformin (1-butybiguanide), 300
            cardiovascular risk factors, 301–2
            cautions and contraindications, 302–3
            clinical outcomes, 301–2
            efficacy, 301
            mechanism of action, 300–1
            metformin (dimethylbiguanide), 300
            phenformin (phenethylbiguanide), 300
            tolerability, 303
        bromocriptine, 314
        classes, 300, 301
            clinical development, 314, 314
        colesevelam, 313–14
dipeptidyl peptidase-4 inhibitors
        alogliptin, 309
        efficacy, 309
        GIP, 307
        GLP-1, 307–8
        incretin effect, 307
        linagliptin, 309
        place, 309
        profiles, 307, 308
        safety and tolerability, 309–10
        saxagliptin, 309
        sitagliptin, 308
        vildagliptin, 308–9
        IDF report, 299
    meglitinides, 306
    risk–benefit profile, 299
    SGLT2 inhibitors
        canagliflozin, 312–13
        dapagliflozin, 312
        efficacy, 311
        empagliflozin, 313
        mechanism of action, 310–11, 311
    sulfonylureas
        mechanism of action, 305
        place, 305
        safety and tolerability, 305–6
    thiazolidinediones
        efficacy, 304
        mechanism of action, 304
        pioglitazone, 303
        rosiglitazone, 303
        safety and tolerability, 304–5
glucose metabolism abnormalities, diagnostic criteria, 34–5, 35
glycemic targets, 380–1
glycosuria, 230
Gold Standard Framework (GSF) Prognostic Indicators, 472
good clinical practice (GCP), 533
growth hormone (GH), 8, 9
HbA1c, 33–4, 36, 356
health‐related quality of life (HRQL), 31, 355
hearing impairment (HI), 423
hepatic glucose production, 5, 5
HHS see hyperglycaemic state (HHS)
high blood pressure, 91–2
homeostasis model assessment (HOMA), 184
homocysteine, 58
hormonal influences, 90
hyperbaric oxygen treatment (HBOT), 121
hyperchloremic metabolic acidosis, 236
hypercoagulability, 78
hyperglycaemic state (HHS), 233
clinical and laboratory follow‐up, 235
clinical presentation, 231
features of, 229
laboratory findings, 232
pathogenesis, 229–31
treatment, 232
hyperglycemia, 477
cardiovascular risk, 69, 77–8
CKD
α‐glucosidases inhibitors, 96–7
DPP‐4 inhibitors, 97
general considerations, 96
glucagon‐like‐peptide‐1 mimetics, 97
insulin, 97
meglitinides, 96
metformin, 96
in pre‐diabetes, 96
sodium‐glucose cotransporter 2 inhibitors, 97
sulfonylureas, 96
diabetes care, inpatient
diabetes education, 401
diabetic foot, 401–2
diabetic ketoacidosis, 398–9
dischARGE planning, 403
dischARGE types, 405, 405
evidence-based criteria, 404
hyperosmolar hyperglycaemic state, 399–400
hypoglycemia, 400–1
initial disCHARGE assessment, 403
meal timings and eating patterns, 403, 403
perioperative care, 402
safe and timely disCHARGE, 403, 403
ThinkGlucose assessment tool, 403–4, 404
HHS, 399–400
specialist feeds composition, 259–60
hyperinsulinemia, 182, 340
hyperinsulinemic euglycemic clamp technique, 180–2
hyperosmolar coma, 225
hyperosmolar hyperglycaemic state (HHS), 399–400
hyper-osmolar nonketotic coma (HONK), 228
hypertension, 25, 38, 382–3
altruist, 341
to avoid polypharmacy, 341
blood pressure
control, 341
measurement, 340
normal, 339
cardiovascular risk, 75–6
CKD
α-blockers, 98
calcium-channel blockers, 98
diuretics, 98
dyslipidemia, 98
fibrates, 98
general considerations, 97
RAAS action, 97–8
statins, 98
thiazide, 98
compliance, with treatment and monitoring, 345
definition, 339
in diabetes
advanced dementia, 346
ambulatory blood pressure measurement, 345–6
end-of-life care, 346–7
frailty, 346
home blood pressure measurement, 346
hypoglycemia episodes, 346
isolated systolic hypertension, 345
older persons, 339
orthostatic hypotension, 345
resistant hypertension, 346
white-coat hypertension, 345
ensure compliance, 341
etiology, 338
guidelines, 339
impact, 339
independence, 341
initiation, 341–2
maintain functionality, 341
micro and macrovascular complications, 341
non-pharmacological management
dietary modifications, 342–3
exercise and regular physical activity, 342
lifestyle changes, 342–4
pharmacological management, 344–5
prevalence, 338, 339
prevent orthostatic hypotension and resultant falls, 341
reduce side effects, 341
hypertriglyceridemia, 199
hypertrophy, 188
hyperuricemia, 38
hypoglycemia, 16–17, 236, 285–6, 285b, 333, 334b, 400–1, 477–8, 478
altered physiological response, 351
care homes, 363
clinical implications
long-term, 354–5
short-term, 354
epidemiology, 351
frailty, 218
glycemic control, 355–6
HbA1c, 356
hierarchy of responses, 352, 352
symptoms, 352–3, 353
treatment modality, 356–7
hypogonadism, 152, 153, 154, 159, 160
hypokalemia, 236
hypothalamic–pituitary–adrenal (HPA) axis, 416, 438, 439
hypovolaemia, 399
impaired fasting glucose (IFG), 33, 70, 180, 190, 240, 438, 519
impaired glucose tolerance (IGT), 21–2, 30, 70, 180, 189, 190, 191, 195, 307, 520
incretin-based therapies, 228
incretin pathway, 7
inflammation, 89–90
Instrumental Activities of Daily Living (IADL) assessment, 49
insulin, 97
insulin aspart, 228
insulin-mediated blood flow, 5, 6
insulin-mediated glucose disposal rates, 5, 6
insulin resistance, 334
and aging, 181
arterial/systemic-hypertension, 191–2
clinical disorders, 181
dyslipidemia, 190–1
glucose intolerance, 189–90
physiological and pathological states, 180
insulin resistance syndrome see metabolic syndrome
insulin therapy, 14, 15, 234
advantages and disadvantages, 324–5, 325b
barrier, 325–6, 326b
in care homes, 330–2
in diabetic patients with dementia, 332, 332
goals, 326
indications, 323–4, 324b
initiation, 326–7, 328b, 330
insulin regimens
basal, 328
basal-bolus, 329
comparison of, 331
premixed, 329–30
physiologic insulin secretion, 327
special considerations, 333–5, 333b
in tube feeding, 332–3
UK Quality and Outcomes Framework (QOF), 379
insulin withdrawal, 335
intensive lifestyle intervention (ILI), 442
intensive lifestyle modification (ILS), 21
intermittent claudication, 61, 62, 64
intermittent hypoxia, 416
interpersonal psychotherapy (IPT), 442
iron, 255
isolated post-challenge hyperglycemia (IPH), 33
isolated systolic hypertension (ISH), 345
ketogenesis, 230
ketosis-prone type 2 diabetes, 229
Kidney Disease/ Improving Global Outcomes guideline (KDIGO), 94
Kussmaul–Kien respiration, 231
latent autoimmune diabetes of the adult (LADA), 492
lean body mass, 183
left ventricular hypertrophy, 68
leg ulceration, 364
life expectancy (LE), 31
lifestyle factors, 4
lifestyle habits, 38–9, 91
lifestyle modification programs, 22–3
linagliptin, 97
lixisenatide, 97
long-duration diabetes, 214
losartan, 76
lower-limb dysfunction, 214
lower urinary tract symptoms (LUTS)
epidemiology, 422
potential explanatory factors, 423
treatment, 423
LysPro insulin, 228
macrovasculopathy, 94–5
magnesium, 235
malnutrition, 240–2
malondialdehyde (MDA), 59
maternally-inherited diabetes and deafness (MIDD), 140
medicine management
adherence, 286–7
antihypertensive medicines, 287
antipsychotic medicines, 287
beliefs and attitudes, 288
blood glucose testing, 287
de-prescribing, 284–5
environment, 293
falls, 287–8
five rights mantra, administration, 288–9
frailty and cognitive changes, 287
health professionals, medicine safety, 288
hypoglycemia, 285–6, 285b
medicine dose aids, 292
medicine errors, 278, 278b
medicine-related vulnerability, 279–80
medicine reviews and risk assessments, 289–92
new medicines, 284
pharmacovigilance, 282, 283–4
polypharmacy, 280–2
renal function, 286
technology and apps, 292–3
under-/malnutrition, 286
meglitinides, 96, 306
metabolic alterations, 5–7
metabolic alterations, hyperglycemia
advanced glycation end products, 88
dyslipoproteinemia, 89
 genetic load and fetal programming, 91
high blood pressure, 91–2
hormonal influences, 90
inflammation, 89–90
lifestyle and habits, 91
obesity, 91
oxidative stress, 88–9
polyol and hexamine contents, 87–8
protein kinase C, 88
renal hemodynamics, 89
uric acid, 89
metabolic decompensation, 225–36
metabolic syndrome, 16
age-related disorders
cognitive dysfunction, 192–3
frailty syndrome, 193–4
anti-obesity drugs, 196–7
anti-platelet therapy, 199
bariatric surgery, 197
blood pressure control, 197
cardiocascular risk factors, 73, 181
clinical definitions, 184–5
in clinical practice, 185–6
components of, 183
IDF clinical criteria, 184, 185
insulin action assessment, 182
insulin physiology and metabolic regulation, 180
insulin resistance
and aging, 181
arterial/systemic-hypertension, 191–2
clinical disorders, 181
dyslipidemia, 190–1
glucose intolerance, 189–90
physiological and pathological states, 180
lipid-modifying drugs, 197–9
medical nutrition therapy, 196
NCEP ATP III clinical criteria, 184
obesity-associated cardiomyopathy, 181–2
pathogenesis, 186
prevalence of, 186
vascular aging, 181
metformin (dimethylbiguanide), 21, 25, 77, 96, 195, 228, 300
absorption, 300
bioavailability, 300
clinical benefits, 302
non-alcoholic fatty liver disease, 417, 418
type 2 diabetes, 300
methicillin-resistant *Staphylococcus aureus* (MRSA) infections, 363
mHealth, type 2 diabetes
architecture, 173–4
block diagram, 173
definition, 168
diabetes management apps, 169–70
organizations, 168
remote management, 168
microalbuminuria, 142, 154, 191, 252, 344, 353, 414
microcirculation, 61
microvasculopathy, 95, 95
middle-age onset diabetes mellitus, 32
miglitol, 306
Mini-Mental State Examination (MMSE), 50, 427–8, 430
Modified Wisconsin Card Sorting Test, 431
molecular biology studies, 8
Montreal Cognitive Assessment (MOCA) tool, 16
mood disorders
anxiety, 439, 440b–2b, 443–4
depression
cognitive dysfunction, 440
and diabetes interaction, 438–9, 439
and diabetes relationship, 438
diagnosis, 439, 440b
ethnicity, 440
management, 440b–2b, 441–3
mortality, 441
physical function, 440–1
distress, 440b–2b, 444
Morley’s mnemonic ‘Meals on Wheels, 248, 249
multidisciplinary care, 334
multifactorial intervention, 78
myocardial infarction, 461
myocardial ischemia, 67
myostatin, 194
NAFLD see non-alcoholic fatty liver disease (NAFLD)
National Adult Reading Test (NART), 428
National Institute of Clinical Excellence (NICE), 38
National Institute of Health and Care Excellence (NICE), 339
National Patient Safety Agency (NPSA), 398, 398
National Service Framework (NSF), 365
negibolol, 197
negative pressure wound therapy (NPWT), 121
nephropathy see also diabetic kidney disease (DKD) 382
primary and community care, 382
neuropathic pain, 462
neutral protamine hagedorn (NPH), 328
nursing care homes, 361
nursing home patients, 387–8
nursing home, screening in, 39
nutritional assessment, 49
nutrition in care homes, 364, 368
nutrition management activity and exercise, 251–2
alcohol, 253
anorexia-sarcopenia-sachexia triad, 242
anthropometric measures, 247
artificial nutrition, 257–8
basis of, 241
calcium, 254
carbohydrates and fats intake, 250–1
chromium, 255
copper, 255
current dietary recommendations, 250
tenteral tube feeding, 258–62
fiber intake, 252
folic acid, 255
guidelines, 249–50
iron, 255
magnesium, 255
malnutrition, 240–2, 242, 248, 249
medications, 248
mnemonic ‘Meals on Wheels, 248, 249
and normal aging, 241–2
nutrition screening, 247, 248
oral nutrition supplements, 256
over-nutrition, 245–6
parenteral nutrition, 261
prebiotics and probiotics, 256
protein intake, 252
sodium intake, 252
under-nutrition BMI and mortality, 243, 244
causes, 243–4
pathologic anorexia, 244–5
prevalence, 242–3
vitamin A and B, 255
vitamin B₁₂, 254–5
vitamin C, 255–6
vitamin D, 253–4
zinc, 255
obesity, 20, 38, 43, 91, 364
adipocytokines, 188
anti-obesity drugs, 196–7
brown adipose tissue, 188
and insulin resistance, 186–9
low-grade inflammation, 188–9
NAFLD, 187–8
over-nutrition, 245–6
oxidative stress, 189
sex steroid hormones, 189
visceral adiposity, 187
obesity-associated cardiomyopathy, 181–2
obstructive sleep apnea (OSA) definition, 415
epidemiology, 415
hypothalamic-pituitary-adrenal axis, 416
intermittent hypoxia, 416
sympathetic nervous system activity, 416
treatment, 416
one-leg stance (OLS) test, 49
opioids, 465
oral glucose tolerance test (OGTT), 32–3
oral nutrition supplements, 256
oral vasodilator prostaglandins, 64
orthostatic hypotension (OH), 450
OSA see obstructive sleep apnea (OSA)
osteoporosis, 253
over-nutrition, 245–6
oxidative stress, 88–9
Paced Auditory Serial Addition Test (PASAT), 427
PAD see peripheral arterial disease (PAD)
pain management acute pain, 458
aged-care homes, 466–7
barriers, 460–1
cancer pain, 459
chronic pain, 458–9
clinical practice, 463
common types, 461
comprehensive pain assessment, 463
descriptors, 456, 457
health professional, 462
non-medicine, 465–6
observation, 464, 464–5
in older person, 466
pain, definition, 457–8
painful diabetic neuropathy, 462
pain tools, 463–4
pharmaceutical treatment, 465
planning, communication, 466
pressure ulcers and wound pain, 462
prevalence of, 459, 460
planning, communication, 466
primary care diabetes team, 378–9, 379
primary care diabetes team, 378–9, 379
primary care practice nurses, 370
protein intake, 252
protein kinase C, 88
protein kinase C activation, 88
}

pharmacovigilance, 282, 283–4, 284
phenformin (phenethylbiguanide), 300
phosphate therapy, 235
physical exercise management
combined resistance and endurance training, 269, 271
duration training, 268, 269, 273
functional capacity, 271–2
in older type 2 diabetic patients, 273–4
resistance training, 268, 269, 270–3
physiologic insulin secretion, 327
pioglitazone, 97
polyol and hexamine contents, 87–8
polypharmacy, 48–9, 280–2, 384
potassium therapy, 234–5
prandial insulin secretion, 327
prebiotics and probiotics, 256
pregabalin, 462
premixed insulin regimens, 329–30
presbyopia, 139
pressure ulcers, 262, 364
primary and community care, 376–88
aspirin therapy, 383
co-morbidities and circumstances
  cognitive impairment, 383–4
dementia, 383–4
depression, 384
polypharmacy, 384
definition, 377
falls, 384–5
frailty, 385–6
glycemic targets, 380–1
individualizing management, 379–80
lifestyle modification, 381
loneliness and social isolation, 387
medication adherence, 386–7, 387
microvascular complications
cardiovascular risk reduction, 382
diabetic foot disease, 382
nephropathy, 382
retinopathy, 381–2
move from hospital to community, 377–8
nursing home patients, 387–8
pharmacotherapy, 381
preventive health care in older people, 388
primary care diabetes team, 378–9, 379
smoking cessation, 382
treatment
dyslipidemia, 383
hypertension, 382–3
UK Quality and Outcomes Framework (QOF), 379
urinary incontinence, 386
primary care diabetes team, 378–9, 379
primary care practice nurses, 370
protein intake, 252
protein kinase C, 88
protein kinase C activation, 88

hypoglycemia, 477–8, 478
key management strategies, 475–6
medicine management, 479, 480
nutrition and hydration, 482
pain management, 476
spiritual needs, 485
type 1 diabetes, 479
type 2 diabetes, 479–81, 481
withdrawal treatment, 484
parenteral nutrition, 261
pathophysiology of diabetes, 3–9
patient-centered approach, 44
Patient Health Questionnaire (PHQ-9), 439
periodontal disease
definition, 423
epidemiology, 424
pathophysiology, 424
treatment, 424
peripheral arterial disease (PAD), 57–65, 115
clinical presentation
  asymptomatic, 61
claudication, 61
critical limb ischemia, 62
diabetic foot, 61
diagnostic methods
  anamnesis and physical assessment, 62–3
  vascular diagnostic techniques, 63–4
epidemiology, 57–8
mortality rate, 57
pathophysiology, 58–61
treatment, 64–5
peroxisome-proliferator activated receptor agonists, 314
pharmacotherapy, 381, 442
pseudoclaudication, 61
public health and community impact
  agenda for action, 522–3, 523b
  economic burden, 517
epidemiology
  age and physical activity, 519
  cholesterol abnormalities and/or high blood pressure, 520
  cognitive impairment, 520
  demographic characteristics, 519
  diet, 519
  frailty, 520
  functional status, 520
  genetic risk factors, 519
  lifestyle, 519
  loneliness, 520
  medical costs, 518
  obesity, 519
  psychological factors, 520
  risk factors, 518
  social group effects, 519
  socioeconomic status, 518–19
heterogeneity, 517
prevalence
  care home residents, 517
  with increasing age, 516–17
  worldwide, 516
prevention
  complications, 521–2
  type 2 diabetes, 520–1, 521b
pump therapy, 335
quality-adjusted life years (QALYs), 527, 528
ramipril, 75
randomized controlled trials (RCTs), 535
recurrent pain, 458
refractive error, 109
removable cast walkers (RCWs), 120
renin hemodynamics, 89
renin-angiotensin aldosterone system (RAAS), 97–8, 340
repaglinide, 96
residential care homes, definition, 361
resistance training, 268, 269, 270–3
resveratrol, 199
retinopathy, 381–2
risk-assessment tools, 38
river blindness (onchocerciasis), 108–9
rosiglitazone, 195
sarcopenia, 61, 194, 218, 218
saxagliptin, 97
screening policy, 36–7
selective serotonin reuptake inhibitors (SSRIs), 442
senile diabetes, 32
sensory disability
  assessment, impairment, 145
  eye screening, 139
  five senses, 137
hearing impairment
  audiological screening, 140
  causes of hearing loss, 140
  communication, 140–1
  deafness, 140
  general population, 139–40
impaired bodily sensation
  cerebrovascular disease, 144
  consequences of, 144, 145
  diabetic neuropathy, 144
  general population, 143–4
  spinal myelopathy, 144
  treatment, 145
medication and sensory impairment, 145
prevention, 137
smelling and tasting
  dementia/Parkinson’s disease, 142
  ‘dose-dependent’ effect, 142
  general population, 141
  multivariate analysis, 142
  and neuropathy, 142–3
  olfactory dysfunction, 141–2
  treatment, 143, 143b
visual impairment
  advice for patients, 138, 139b
  Charles Bonnet syndrome, 138–9
  communication, 139
  diabetic retinopathy, color vision, 138
  eye screening, 139
  general population, 138, 138
  macular edema, 138
  visual problems, diabetes mellitus, 138, 139b
serum albumen, 249
sexual health and wellbeing
  in aging
    dissatisfaction, sex life, 149, 150
    symptoms and complaints, 150–1
    UK changes, 148, 149
  androgen ablation therapy, 161
  cardiovascular medications, 158–9
  cognitive function, 160
hormones and aging, men
  angina threshold and heart failure, 152
  biochemical assessment, hypogonadism, 152
  implications, medicine practice, 154–5, 155
  implications, pharmacotherapy, 155–6
  lifestyle interventions, 153
  low testosterone and mortality, 152
  testosterone, IR, and type 2 diabetes, 153
  testosterone replacement therapy, 153–4, 154
TRT effects, 152
TRT, weight, BMI and waist circumference, 154
long-term safety, testosterone therapy, 161
mood and depression, 160
in older age, 148
osteoarthritis, 159
recurrent falls, 159
testosterone
and Alzheimer's disease, 160
and quality of life, 160–1
in women
cor-morbid conditions, 156, 157
depression, 157–8
FSFI scores, 156, 157
lifestyle interventions, 158
thyroid disease, 157
SGLT2 inhibitors see sodium-glucose co-transporter type 2 (SGLT2) inhibitors
shear stress in glomerular structure, 89
Short Physical Performance Battery (SPPB), 49
silent hypoglycemia, 226
simvastatin, 199
sirtuin activators, 199
sitagliptin, 97
smoking
cardiovascular risk, 71
primary and community care, 382
as risk factor for peripheral arterial disease, 58
sodium-glucose co-transporter type 2 (SGLT2) inhibitors, 97
canagliflozin, 312–13
dapagliflozin, 312
efficacy, 311
empagliflozin, 313
mechanism of action, 310–11, 311
sodium intake, 252
statins, 98
lowering cholesterol, 73
statin therapy, 197–9
Stroop test, 432
subacute pain, 458
Subjective Memory Questionnaire, 431
sudomotor dysfunction, 129
sulfonamides, 228
sulfonylureas, 96
mechanism of action, 305
place, 305
safety and tolerability, 305–6
Summary of Diabetes Self Care Activities (SDSCA), 431
swallowing, 262
sympathetic nervous system, 340, 416
symptomatology, 32

Tarsal tunnel syndrome, 127
therapeutic education, 48
thiazide, 98, 344
thiazide diuretics, 76
thiazolidinediones (TZDs), 96, 417, 419
efficacy, 304
mechanism of action, 304
pioglitazone, 303
rosiglitazone, 303
safety and tolerability, 304–5
thienopyridines, 64
ThinkGlucose assessment tool, 403–4, 404
Timed Test of Money Counting test, 50
Timed Test of Money Counting test, 49
total contact casts (TCCs), 120
Trail Making B (TMB), 427
trauma, 109
tricyclic antidepressants (TCA), 442
troglitazone, 195
two-hour plasma glucose (2h-PG), 33, 36
type 1 diabetes mellitus
caregivers, 17
cor-morbidities, 15–16
complications, 14–16
hypoglycemia, 16–17, 350–7, 351
long-term care, 17
management of, 13–14
personal and community resources, 17
vs. type 2 diabetes, 13, 14
type 2 diabetes mellitus
characteristics of, 13, 14
clinical decision-making, 171, 172
coronary artery disease, 299
DPP-4 inhibitors, 299
estimated prevalence, 323
formal caregiver, 172
functional model, 172–3
hypoglycemia, 351
incidence rate, 170
informal caregiver, 172
insulin therapy, 323–35
management, 299
medications, 21
mHealth
architecture, 173–4
block diagram, 173
definition, 168
diabetes management apps, 169–70
organizations, 168
remote management, 168
multimodal approach, 171–2
prevalence, 170
randomized controlled trials, 21, 22
risk minimization care plan, 171
risk of disability, 171
risk of frailty, 171
type 2 diabetes mellitus (cont’d)
  self-management, 171
  SGLT2 inhibitors, 299
  stroke, 299
  thiazolidinediones, 299
  treatment, 323
  vs. type 1 diabetes, 13, 14

UK National Diabetes Inpatient Audit (NaDIA), 395
under-nutrition
  BMI and mortality, 243, 244
  causes, 243–4
  pathologic anorexia, 244–5
  prevalence, 242–3
United States Preventive Service Task Force (USPSTF), 38
uric acid, 89
urinary incontinence, 364
  primary and community care, 386
urinary tract infections (UTIs), 421
vascular thrombosis, 236
vasodilatation, 68
venlafaxine, 133
vildagliptin, 97
visceral adiposity, 187
visual impairment, causes, 107–208, 107b, 108b
visual loss
  age-related macular degeneration, 109–10
  cataract, 109
  cytomegalovirus, in human immunodeficiency, 109
  diabetic retinopathy, 110
  evidence-based review, 108, 108b
  glaucoma, 109
  global impact, 107, 107b
  infectious causes, 108
  legal blindness (USA), 106
  legal blindness (World Health Organization, WHO), 106
  legal blindness UK, 106
  refractive error, 109
  river blindness (onchocerciasis), 108–9
  trauma, 109
  vitamin A deficiency, 109
vitamin A and B, 255
vitamin A deficiency, 109
vitamin B12 (cobalamin), 254–5
vitamin C, 255–6
vitamin D, 253–4
vitamin D deficiency, 90
vitamin E, 64
weight reduction, 71
Whipple’s triad, 351
zinc, 255